Clinical Analysis Of Peripheral Blood Stem Cell Transplantation In The Treatment Of Malignant Lymphoma In 110 Cases

Objective To investigate the curative effect of peripheral blood stem cell transplantation (PBSCT) in the treatment of malignant lymphoma, and evaluate the prognostic factors of the patients with malignant lymphoma.Methods 110 cases of malignant lymphoma patients, including 12 cases of Hodgkin’s lymphoma and 98 cases of non-Hodgkin’s lymphoma (63 cases of B-cell and 35 cases of T/NK-cell), who treated with PBSCT in the hematology department of our hospital from November 2007 to April 2015 were admitted.104 patients were treated with autologous hematopoietic stem cell transplantation, while 6 patients accept allogeneic hematopoietic stem cell transplantation. Among the patients with B-cell non-Hodgkin’s lymphoma,33 cases of them were treated with the combination use of Rituximab, While, another 30 patients without the addition Rituximab.Results Enough peripheral blood hemopoietic stem cell were collected from the patients who accepted autologous hematopoietic stem cell transplantation after the mobilization. All of the patients, excepted two died of septicopyemia, achieved hematopoietic reconstitution after transplantation. The median time to achieve an absolute neutrophil count above 0.5×109/L was 9 (7-18)d, and the median time of the absolute platelet count recovery to> 20×109/L was 12 (6-94)d. With the follow-up of 25 (1-113) months,92 (83.64%) patients were alive, of which 15 (13.63%) lived with disease and 29 (26.36%) were relapsed. The 3-year overall survival rate (OS) and progression-free survival rate (PFS) were 80.00% and 70.00%. The 3-year OS and PFS rate in the patients with B-cell Non-Hodgkin’s lymphoma were 92% and 82%, while 56% and 48% in the paitients with T-cell Non-Hodgkin’s lymphoma, and the OS and PFS of the two groups have significant statistical difference (P=0.000/P=0.000). The 3-year OS of the low LDH level group and high LDH level group were 86% and 60%, meanwhile, the 3-year PFS were 80% and 36% and had statistically significant differences(P=0.000). The 3-year PFS in paitients achieved CR before transplantation was 82%, while 46% in the paitients who hadn’t achieved CR, and the PFS between the two groups have no significant statistical difference(P=0.058). The 3-year OS and PFS in the patients who treated with the combination use of Rituximab and chemotherapy were (97%) and (89%), while (83%) and (71%) in the patients accepted the treatment without Rituximab, and the OS and PFS of the two groups have no statistical difference (P=0.315/P=0.135).Conclusions PBSCT is a safe and effective method for the treatment of lymphoma. T-cell Non-Hodgkin’s lymphoma and high LDH values are the independent adverse prognostic factors for lymphoma.